Nanobac Life Sciences, Inc. And Fetzer Memorial Trust Enter Groundbreaking Collaboration To Photograph Never Before Seen Calcification Mechanism
Published: Aug 08, 2006
TAMPA, Fla.--(BUSINESS WIRE)--Aug. 8, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") today announced it has entered into a collaboration agreement with the Fetzer Memorial Trust to photograph the replication cycle of disease-related calcifying particles (also known as nanobacteria or Calcifying Nanoparticles), using light microscopes to break the 200 nanometer ("nm") resolution barrier. The breakthrough allows Nanobac scientists to determine if calcification, which occurs in most diseases on the leading causes of death list, has a biological mechanism, which would make it susceptible to therapy. Results could generate new approaches to the treatment of calcifying diseases such as heart disease, kidney stones and diabetes, and validate the significance of related Nanobac diagnostics and therapies.